A 42-year-old woman with biopsy-proven pulmonary TB on standard HRZE therapy for 2 months reports persistent productive cough, fever, and weight loss. Repeat sputum smear microscopy remains positive for AFB. CXR shows no radiological improvement. She reports good adherence to medications. What is the most appropriate next step in management?

Question

Accepted Answer

B. Send sputum for drug susceptibility testing (DST) and culture; consider MDR-TB. ## Clinical Context This patient demonstrates **treatment failure** — persistent sputum smear positivity after 2 months of appropriate first-line therapy with documented adherence. This is a red flag for drug resistance, particularly MDR-TB. ## Definition and Significance of TB Treatment Failure **Key Point:** Treatment failure is defined as: - Sputum smear or culture remaining positive after 2 months of supervised first-line ATT, OR - Sputum becoming positive again after initial conversion (relapse/recurrence) **High-Yield:** Treatment failure strongly suggests **drug-resistant TB (MDR-TB or XDR-TB)** and requires urgent DST to guide second-line therapy. ## Management Algorithm for Treatment Failure ```mermaid flowchart TD A["Sputum smear positive after 2 months ATT"]:::outcome --> B{"Adherence confirmed?"}:::decision B -->|"Yes (as in this case)"| C["Send sputum for DST/culture"]:::action B -->|"No"| D["Reinforce adherence, DOT"]:::action C --> E{"DST Result?"}:::decision E -->|"MDR-TB confirmed"| F["Start 2nd-line regimen
Fluoroquinolone + Injectable
+ Bedaquiline/Linezolid"]:::action E -->|"Drug-susceptible TB"| G["Review adherence, absorption
Malabsorption workup"]:::action E -->|"Pending"| H["Empiric 2nd-line therapy
if high MDR-TB risk"]:::action ``` ## Why Each Option Is or Isn't Correct | Option | Rationale | | --- | --- | | **Continue HRZE** | ❌ Incorrect. Persistent positivity after 2 months is treatment failure, not delayed conversion. Continuing the same drugs risks further resistance. | | **Send DST + culture** | ✅ **CORRECT.** This is the standard next step. DST will identify resistance pattern and guide second-line therapy selection. | | **Switch to fluoroquinolones alone** | ❌ Incorrect. Monotherapy with fluoroquinolones is inadequate and promotes further resistance. Must wait for DST to guide proper 2nd-line regimen. | | **Add bedaquiline/linezolid immediately** | ❌ Incorrect. Second-line agents are added only after DST confirms MDR-TB. Premature use without DST is wasteful and promotes resistance. | **Clinical Pearl:** The window for DST result (culture takes 2–4 weeks; LPA takes 2–3 days) is bridged by: - Reinforcing adherence and DOT - Investigating malabsorption (TB-HIV co-infection, GI TB, drug interactions) - **Empiric second-line therapy** is considered only in high-risk settings (HIV+, prior TB treatment, known MDR-TB contact) while awaiting DST. **Mnemonic:** **FAIL → DST** — Treatment Failure → Drug Susceptibility Testing (mandatory before 2nd-line drugs).

Answer

A. Switch to fluoroquinolone-based regimen immediately without waiting for DST results

Answer

C. Continue the same HRZE regimen for the full 6-month duration; smear conversion may take 3–4 months

Answer

D. Add second-line agents (bedaquiline, linezolid) to the current regimen

Explanation

Clinical Context

Definition and Significance of TB Treatment Failure

Management Algorithm for Treatment Failure

Why Each Option Is or Isn't Correct

Practice similar questions

Join our NEET PG community

Option	Rationale
Continue HRZE	❌ Incorrect. Persistent positivity after 2 months is treatment failure, not delayed conversion. Continuing the same drugs risks further resistance.
Send DST + culture	✅ CORRECT. This is the standard next step. DST will identify resistance pattern and guide second-line therapy selection.
Switch to fluoroquinolones alone	❌ Incorrect. Monotherapy with fluoroquinolones is inadequate and promotes further resistance. Must wait for DST to guide proper 2nd-line regimen.
Add bedaquiline/linezolid immediately	❌ Incorrect. Second-line agents are added only after DST confirms MDR-TB. Premature use without DST is wasteful and promotes resistance.